Etanercept (German Wikipedia)

Analysis of information sources in references of the Wikipedia article "Etanercept" in German language version.

refsWebsite
Global rank German rank
4th place
7th place
2nd place
3rd place
low place
low place
1st place
1st place
33rd place
2nd place
low place
1,805th place

apotheke-adhoc.de

  • Apotheke Adhoc: Erelzi: Enbrel von Hexal. In: APOTHEKE ADHOC. (apotheke-adhoc.de [abgerufen am 26. November 2018]).

discoverymedicine.com

doi.org

  • Yohei Mukai, Teruya Nakamura, Mai Yoshikawa, Yasuo Yoshioka, Shin-ichi Tsunoda: Solution of the structure of the TNF-TNFR2 complex. In: Science Signaling. Band 3, Nr. 148, 16. November 2010, S. ra83, doi:10.1126/scisignal.2000954, PMID 21081755.
  • Stephane Houel, Mark Hilliard, Ying Qing Yu, Niaobh McLoughlin, Silvia Millan Martin: N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. In: Analytical Chemistry. Band 86, Nr. 1, 7. Januar 2014, S. 576–584, doi:10.1021/ac402726h, PMID 24308717.
  • William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel: The structure-function relationship of disulfide bonds in etanercept. In: Scientific Reports. Band 7, Nr. 1, 21. Juni 2017, S. 3951, doi:10.1038/s41598-017-04320-5, PMID 28638112, PMC 5479810 (freier Volltext).
  • Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. In: Clin. Infect. Dis. 39. Jahrgang, Nr. 3, August 2004, S. 295–299, doi:10.1086/421494, PMID 15306993.
  • Nagwa Mostafa El-Sayed, Khadiga Ahmed Ismail, Abeer Fathy Badawy, Khaled Fathy Elhasanein: In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis. In: Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology. Band 40, Nr. 4, Dezember 2016, S. 1459–1465, doi:10.1007/s12639-015-0712-y, PMID 27876967, PMC 5118338 (freier Volltext).
  • Jing Yang, Luyao Wang, Dongmei Xu, Ding Tang, Senyang Li: Risk Assessment of Etanercept in Mice Chronically Infected With Toxoplasma gondii. In: Frontiers in Microbiology. Band 9, 2018, S. 2822, doi:10.3389/fmicb.2018.02822, PMID 30519229, PMC 6258779 (freier Volltext).
  • Bénédicte De Vroey, Michael Schapira, Jean-Michel Ghilain: A Terminal Event New England Journal of Medicine 2019, Band 381, Ausgabe 22 vom 28. November 2019, Seite 2183, DOI:10.1056/NEJMc1913325

nih.gov

ncbi.nlm.nih.gov

  • R. L. Yung: Etanercept Immunex. In: Current opinion in investigational drugs (London, England : 2000). Band 2, Nummer 2, Februar 2001, S. 216–221, PMID 11816834 (Review).
  • Yohei Mukai, Teruya Nakamura, Mai Yoshikawa, Yasuo Yoshioka, Shin-ichi Tsunoda: Solution of the structure of the TNF-TNFR2 complex. In: Science Signaling. Band 3, Nr. 148, 16. November 2010, S. ra83, doi:10.1126/scisignal.2000954, PMID 21081755.
  • Stephane Houel, Mark Hilliard, Ying Qing Yu, Niaobh McLoughlin, Silvia Millan Martin: N- and O-glycosylation analysis of etanercept using liquid chromatography and quadrupole time-of-flight mass spectrometry equipped with electron-transfer dissociation functionality. In: Analytical Chemistry. Band 86, Nr. 1, 7. Januar 2014, S. 576–584, doi:10.1021/ac402726h, PMID 24308717.
  • William C. Lamanna, Robert Ernst Mayer, Alfred Rupprechter, Michael Fuchs, Fabian Higel: The structure-function relationship of disulfide bonds in etanercept. In: Scientific Reports. Band 7, Nr. 1, 21. Juni 2017, S. 3951, doi:10.1038/s41598-017-04320-5, PMID 28638112, PMC 5479810 (freier Volltext).
  • Gardam MA, Keystone EC, Menzies R, et al.: Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. In: Lancet Infect Dis. 3. Jahrgang, Nr. 3, März 2003, S. 148–55, PMID 12614731.
  • Keane J, Gershon S, Wise RP, et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. In: N. Engl. J. Med. 345. Jahrgang, Nr. 15, Oktober 2001, S. 1098–1104, PMID 11596589.
  • Mohan AK, Coté TR, Block JA, Manadan AM, Siegel JN, Braun MM: Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. In: Clin. Infect. Dis. 39. Jahrgang, Nr. 3, August 2004, S. 295–299, doi:10.1086/421494, PMID 15306993.
  • Nagwa Mostafa El-Sayed, Khadiga Ahmed Ismail, Abeer Fathy Badawy, Khaled Fathy Elhasanein: In vivo effect of anti-TNF agent (etanercept) in reactivation of latent toxoplasmosis. In: Journal of Parasitic Diseases: Official Organ of the Indian Society for Parasitology. Band 40, Nr. 4, Dezember 2016, S. 1459–1465, doi:10.1007/s12639-015-0712-y, PMID 27876967, PMC 5118338 (freier Volltext).
  • Jing Yang, Luyao Wang, Dongmei Xu, Ding Tang, Senyang Li: Risk Assessment of Etanercept in Mice Chronically Infected With Toxoplasma gondii. In: Frontiers in Microbiology. Band 9, 2018, S. 2822, doi:10.3389/fmicb.2018.02822, PMID 30519229, PMC 6258779 (freier Volltext).

redirecter.toolforge.org

  • BUSINESS WIRE: Samsung Bioepis tritt mit Benepali® – dem ersten von der EU-Kommission zugelassenen Fusionsprotein-Biosimuar (sic!) – in den europäischen Biopharma-Markt ein. Finanztreff, archiviert vom Original am 10. Februar 2016; abgerufen am 10. Februar 2016.

web.archive.org

  • BUSINESS WIRE: Samsung Bioepis tritt mit Benepali® – dem ersten von der EU-Kommission zugelassenen Fusionsprotein-Biosimuar (sic!) – in den europäischen Biopharma-Markt ein. Finanztreff, archiviert vom Original am 10. Februar 2016; abgerufen am 10. Februar 2016.